Additionally, a novel dual-targeting CRISPR screening approach developed by Klingbeil et al. identified the MARK2/3 kinases as genetic co-dependencies of YAP and TAZ across a wide range of YAPon cancers, including pancreatic adenocarcinoma, breast, NSCLC, and rhabdomyosarcoma [96]. Here, MARK2 is linked to cancer.